Developmental origins and oncogenic pathways in malignant brain tumors

Area of Science:

• Neuro-oncology
• Genomics
• Epigenomics

Background:

• Malignant brain tumors like glioblastomas and medulloblastomas have poor prognoses.
• Tumor heterogeneity and therapy resistance are linked to cell of origin and genetic alterations.
• Brain tumor development mirrors neurogenesis but with dysregulated growth.

Purpose of the Study:

• To review current understanding of brain tumor cells of origin, heterogeneity, and molecular alterations.
• To discuss oncogenic drivers and signaling pathways in adult glioblastomas, pediatric high-grade gliomas, and medulloblastomas.
• To highlight how new classifications based on molecular profiles inform treatment strategies.

Main Methods:

• Comprehensive genomic, transcriptomic, and epigenomic analyses.
• Single-cell resolution studies.
• Review of existing literature on brain tumor genetics and epigenetics.

Main Results:

• Brain tumors arise from various neural cell types, leading to heterogeneity.
• Distinct genetic alterations (e.g., EGFR amplification, IDH1/2, TP53, H3K27M mutations) define tumor subtypes.
• Identification of molecular and lineage-specific vulnerabilities for treatment stratification.

Conclusions:

• Understanding tumor cell of origin and heterogeneity is crucial for brain tumor treatment.
• New classifications based on molecular profiles improve insights into treatment strategies.
• Targeting molecular and lineage-specific vulnerabilities holds promise for improved outcomes.